Literature DB >> 15585402

Adenovirus protein IX: a new look at an old protein.

Robin J Parks1.   

Abstract

The success of gene therapy depends in part on our understanding of the biology of gene therapy vectors. This knowledge must be used to improve the function, safety, and versatility of the vector system. For decades, we have known which viral proteins are involved in formation of the adenovirus (Ad) capsid, but we are still learning how these proteins can be altered or manipulated to improve vector function. The Ad protein IX (pIX) was originally identified as a minor component of the Ad capsid, but was not essential for virion formation. However, more recent studies have suggested that pIX may have multiple roles in the Ad life cycle, including acting as a transcriptional activator and reorganizing nuclear proteins to provide an environment more conducive to virus replication. In gene therapy studies, removal of pIX from the Ad vector backbone was used to increase the cloning capacity of E1-deleted Ad vectors and to develop a new method for preparing helper-dependent Ad vectors. pIX has also been at the center of numerous attempts to eliminate the problem of replication-competent Ad in Ad vector preparations. Finally, pIX represents a versatile platform for the presentation of polypeptides on the surface of the viral capsid, including ligands for virus retargeting and fluorescent proteins for visualizing the virus in vitro and in vivo. Thus, the importance and uses of this "minor" capsid protein have changed significantly over the past few years.

Mesh:

Substances:

Year:  2005        PMID: 15585402     DOI: 10.1016/j.ymthe.2004.09.018

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  40 in total

1.  Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Zachary C Hartman; Nathaniel J Schuldt; Jeannine Scott; Sarah Godbehere; Haixiang Jiang; Michael M Frank; Andrea Amalfitano
Journal:  Blood       Date:  2010-05-28       Impact factor: 22.113

Review 2.  Viral and cellular interactions during adenovirus DNA replication.

Authors:  Matthew Charman; Christin Herrmann; Matthew D Weitzman
Journal:  FEBS Lett       Date:  2019-12-17       Impact factor: 4.124

3.  Fusion of Large Polypeptides to Human Adenovirus Type 5 Capsid Protein IX Can Compromise Virion Stability and DNA Packaging Capacity.

Authors:  Kathy L Poulin; Emily R McFall; Grace Chan; Natacha B Provost; Carin Christou; Adam C Smith; Robin J Parks
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

4.  Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion.

Authors:  Qiana L Matthews; Don A Sibley; Hongju Wu; Jing Li; Mariam A Stoff-Khalili; Reinhard Waehler; J Michael Mathis; David T Curiel
Journal:  Mol Imaging       Date:  2006 Oct-Dec       Impact factor: 4.488

Review 5.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

6.  Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Authors:  Anja Krause; Ju H Joh; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal; Stefan Worgall
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  Cryoelectron microscopy of protein IX-modified adenoviruses suggests a new position for the C terminus of protein IX.

Authors:  Michael P Marsh; Samuel K Campos; Matthew L Baker; Christopher Y Chen; Wah Chiu; Michael A Barry
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

8.  Thermostability/infectivity defect caused by deletion of the core protein V gene in human adenovirus type 5 is rescued by thermo-selectable mutations in the core protein X precursor.

Authors:  Hideyo Ugai; Anton V Borovjagin; Long P Le; Minghui Wang; David T Curiel
Journal:  J Mol Biol       Date:  2006-12-06       Impact factor: 5.469

Review 9.  Current advances and future challenges in Adenoviral vector biology and targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Curr Gene Ther       Date:  2007-06       Impact factor: 4.391

10.  DNA genome size affects the stability of the adenovirus virion.

Authors:  Adam C Smith; Kathy L Poulin; Robin J Parks
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.